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Abstract
This study investigated the effects of two selective serotonin2C (5-hydroxytryptamine, 5-HT2C) receptor-acting compounds into the 
ventral hippocampus (VH) of rats exposed to the elevated plus-maze (EPM). In the first experiment, rats were exposed to the EPM 10 min 
following VH infusions of either vehicle or the selective 5-HT2C-receptor agonist RO-60-0175 (0.3, 1.0, 3.0 and 10.0µg). In addition to 
conventional parameters of open arm exploration (i.e. percentages of open arm entries and of time spent in these arms), risk assessment-
related behaviors were recorded as anxiety-like measures in EPM scoring. RO-60-0175 selectively decreased open arm exploration at 
the dose of 1.0 µg, while inducing locomotor-suppressant effects at the two highest doses. In the second experiment, VH infusions of 
the selective 5-HT2C antagonist RS 102221 (0.75, 1.25 and 2.5 µg) did not affect open arm exploration, while reducing risk assessment 
in the closed ones. This behavioral profile of risk assessment is suggestive of an anxiolytic-like action. These results further corroborate 
our previous findings showing that VH 5-HT2C receptor activation elicits anxiogenic-like and locomotor-suppressant effects, and suggest 
that the selective blockade of this receptor is accompanied by an anxiolytic-like action as detected by ethologically derived measures in 
the EPM. Keywords: anxiety, 5-HT2C receptors, RO-60-0175, RS 102221, ventral hippocampus, elevated plus-maze, risk assessment. 
Introduction
Serotonin2C (5-hydroxytryptamine, 5-HT2C) receptor 
activation, either by nonselective 5-HT2C agonists such as 
m-chlorophenylpiperazine (m-CPP) and trifluoromethyl-
phenylpiperazine (TFMPP) or the preferential 5-HT2C 
agonist 6-chloro-2[1-piperazinyl]pyrazine (MK-212), 
has long been associated with anxiogenic-like profiles 
in a variety of animal models of anxiety, including the 
elevated plus-maze (EPM; Benjamin, Lal, & Meyerson, 
1990; Kshama, Hrishikeshavan, Shanbhogue, & 
Munonyedi, 1990; Rodgers et al., 1992; Gibson et 
al., 1994; Griebel, Moreau, Jenck, Mutel, Martin, & 
Misslin, 1994; Fone,  Shalders, Fox, Arthur, &  Marsden, 
1996; Wallis and Lal, 1998; Setem, Pinheiro, Motta, 
Morato, & Cruz, 1999; Jones, Duxon, & King, 2002; Bull, 
Huston, & Fone , 2003; Durand, Mormèd, & Chaouloff, 
2003). In fact, newly selective 5-HT2C agonists (e.g. RO-
60-0175) have been found to increase anxiety-related 
behaviors (Griebel et al., 1997; Kennett, et al., 1997, 
Kennett, Lightowler, S., Trail, Bright, & Bromidge, 2000; 
Martin, Ballard, & Higgins, 2002; Millan, Brocco, Gobert, 
& Dekeyne , 2005), although null and even anxiolytic-like 
effects have also been reported (Nic Dhonnchadha, Bourin, 
& Hascoet, 2003; Rippol, Hascoet, & Bourin, 2006). 
Despite growing insights into the neural mechanisms 
through which 5-HT systems might influence defensive 
behavior, the circuits responsible for the above findings as 
well as the exact role of the 5-HT2C receptor in specific types 
of anxiety remain unclear. For example, 5-HT2C agonists 
increase anxiety-related behaviors in the basolateral nucleus 
of the amygdala (Campbell & Merchant, 2003) but decrease 
panic-related behaviors in the dorsal periaqueductal gray 
(Jenck, Bos, Wichmann, Stadler, Martin, & Moreau, 1998; 
Graeff, 2002; Jacob et al., 2002; Zanoveli, Nogueira, & 
Zangrossi, 2003). Therefore, different brain structures that 
receive direct 5-HT projections from the dorsal raphe nucleus 
might have a distinct contribution to anxiety mediation.  
 Besides the amygdala and the periaqueductal gray, 
the ventral portion of the hippocampus (VH) is another 
important postsynaptic 5-HT site whose cell bodies are 
located in the dorsal raphe nucleus (Azmitia & Segal, 
1978; Vertes, 1991). It appears that 5-HT receptors present 
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in the VH are involved in defensive behavior. For example, 
it has been found that electric stimulation of the dorsal 
raphe nucleus (McQuade & Sharp, 1997) or potentially 
dangerous situations such as a context previously associated 
to a footshock (Hajos-Korcsok, 2003) and acute EPM 
exposure (Wright, Upton, & Marsden, 1992; Voigt, Rex, 
Sohr, & Fink, 1999; Rex, Voigt, & Fink, 2005) enhance 
postsynaptic 5-HT levels in the VH, which may suggest 
an anxiogenic-like role for 5-HT within this forebrain 
site. In agreement with this view, selective VH lesions are 
associated with anxiolytic-like effects in contextual fear 
conditioning (Bannerman, Grubb, Deacon, Yee, Feldon, 
& Rawlins , 2003, Bannerman et al., 2004), light-dark 
transition (Kjelstrup, Tuvnes, Steffenach, Murison, Moser, 
& Moser, 2002; McHugh, Deacon, Rawlins, & Bannermen, 
2004), social interaction test in rats (McHugh et al, 2004) 
and in the EPM (Bannerman et al., 2002; Kjelstrup et al., 
2002; Degroot & Treit, 2004).
Interestingly, the fibers originating from the dorsal raphe 
nucleus establish preferential contact with postsynaptic 
5-HT2 receptors (Mammounas  Mullen, O’Hearn, & 
Molivier, 1991). Based upon results showing the presence 
of the 5-HT2C receptor subtype at a very high density in 
the VH (Pompeiano, Palácios, & Mengod, 1994; Fone, 
Shalders, Fox, Arthur., &  Marsden 1996, Clemett, Punhani, 
Duxon, Blackburn, & Fone, 2000; Garcia-Alcover, Segura, 
Garcia Pena, Martinez-Torres, & Miledi, 2006), however 
being more abundant in the choroid plexus (Leysen, Van 
Gompel, Gommeren, Weestenborghs, & Jansen, 1986; 
Backstrom, Westphal, Canton, & Sanders-Bush, 1995; 
Leysen, 2004), it is possible that the anxiogenic-like role 
of 5-HT in the VH might be, at least in part, mediated 
via 5-HT2C receptor activation. Accordingly, in another 
study, we found the preferential 5-HT2C agonist MK-212 
to elicit anxiogenic-like effects when infused directly into 
the ventral but not dorsal hippocampus of rats exposed to 
the EPM (Alves, Pinheiro, Motta, Landeira-Fernandez, & 
Cruz 2004).
It is of note that although MK-212 does not act 
selectively at 5-HT2C receptors, its effects have been usually 
attributed to a 5-HT2C-receptor activation on the basis of 
receptor binding (nM affinity for 5-HT2C receptor and 
> 16-fold lower for 5-HT2 receptor subtypes; Porter et al., 
1999) and behavioral findings showing a clear dependence 
of discriminative action on selective stimulation of 5-HT2C 
receptors (Clineschmidt, 1979; Blackburn, Kemp, Martin, 
& Cox, 1984; Cunningham, Callahan, & Appel, 1986). 
Therefore, such an MK-212-induced anxiogenic-like effect 
in the VH is likely to be due to a 5-HT2C-receptor activation, 
although the participation of other 5-HT2 receptors cannot 
be totally discounted. 
The present study employed two newly selective 
5-HT2C-acting compounds in order to further investigate 
the role of VH 5-HT2C receptors in mediating anxiety-like 
behaviors triggered by the EPM. In Experiment 1, rats were 
exposed to the EPM under the effects of intra-VH infusion 
with the selective 5-HT2C-receptor agonist RO-60-0175, 
a centrally acting compound that exhibits high affinity for 
the 5-HT2C-receptor (nM affinity for 5-HT2C and > 25 – 
100-fold lower for other receptors; Boes et al., 1997; Porter 
et al., 1999). Although RO-60-0175 presents considerable 
selectivity for 5-HT2A and 5-HT2B receptors (Vickers et al., 
2001; Knight et al., 2004), this compound seems to produce 
predominantly 5-HT2C-receptor mediated behavior (Martin 
et al., 1998). This conclusion is supported by results in 
which highly selective 5-HT2C antagonists, such as SB-
242084 (Martin, Ballard, & Higgins, 2002), but not 5-HT2A 
or 5-HT2B antagonists (Dekeyne, Girardon, & Milan, 1999) 
prevent changes in behavior induced by R0-60-0175. 
These patterns of results support the use of RO-60-0175 in 
several laboratories as a reliable pharmacological tool for 
activating 5-HT2C receptors.
 Considering that VH 5-HT2C-receptor activation might 
elicit an anxiogenic-like effect, it is reasonable to assume 
that the selective blockade of this receptor subtype might 
be accompanied by an anxiolytic-like action. Experiment 
2 tested this hypothesis by infusing the selective 5-HT2C-
receptor antagonist RS 102221 directly into the VH. RS 
102221 is a centrally acting antagonist that binds with 
high affinity to 5-HT2C receptors (nM affinity for 5-HT2C 
and > 35-fold lower for other 5-HT2 receptor subfamilies; 
Bonhaus et al., 1997). To the best of our knowledge, the 
effects of RS 102221 on anxiety-like behaviors in the EPM 
have not yet been described.  
Methods
Subjects
Experimentally naive male Wistar rats weighing 190-
250 g were employed as subjects. The animals were born 
and raised in the vivarium at the University of Brasilia. 
One week before the study they were brought to the 
holding room of the laboratory facilities and housed in 
groups of two in polycarbonate cages measuring 30 × 30 × 
50 cm. All the rats had free access to food and water. Room 
temperature was controlled (25 + 1oC) and light-dark cycle 
was maintained on a 12-h on-off cycle (07:00-19:00h lights 
on). The experimental sessions were carried out during the 
light phase of the cycle. The experimental protocols were 
conducted in conformity with the recommendations of the 
Brazilian Society of Neuroscience and Behavior (SBNeC), 
which are based on the US National Institutes of Health 
Guide for the Care and Use of Laboratory Animals (revised 
in 1996).
Surgery 
Animals were anaesthetized with sodium thiopental (45 
mg/kg IP) and placed in a stereotaxic frame with the head 
level between bregma and lambda. A subcutaneous injection 
of 2% lidocaine with vasoconstrictor was administered in 
the surgical area until a small bubble was formed. Each rat 
was bilaterally implanted with a stainless steel guide cannula 
(o.d. 0.7 mm) aimed at 0.5 mm above the target area. Taking 
bregma as the reference for each plane according to the 
Paxinos and Watson atlas (1986), the coordinates were 
4.8 mm posterior to bregma, 5.0 mm lateral to the midline 
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for each hemisphere, and 5.5 mm ventral to skull. Guide 
cannulae were anchored to the skull by means of dental 
acrylic and four stainless screws. After implantation, the 
guide cannulae were sealed with a stainless steel wire to 
prevent eventual congestion. Four days after surgery the 
animals were wrapped in a cloth and handled for 3 min for 
three consecutive days. Behavioral testing was performed 
on the 8th day post-surgery. 
Apparatus 
The EPM, elevated 50 cm above the ground, consisted 
of two open arms (50 × 10 cm) perpendicular to two other 
arms of the same size enclosed by 40 cm-high walls. These 
four arms delimited a central area of 10 × 10 cm. A rim of 
Plexiglas (1 cm high) surrounded the perimeter of the open 
arms to minimize rats falling off the maze. Illumination 
was provided by a dim light bulb (60 W) in the ceiling of 
the experimental room and the light intensity in the center 
of the maze was adjusted to 55 lux. A video camera linked 
to a monitor and VCR in an adjacent room videotaped the 
experimental sessions. 
Drugs
RS 102221 [8-5[5-(2,4-dimethoxy-5-(4-trifluoro me thyl -
phenyl-sulphoamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro-
[4.5]decane-2,4-dione HCl] and  RO-60-0175  [(S)-2-(6-
chloro-5-floro-indol-l-yl)-1-methyl-amine fumarate] (Tocris, 
Ballwin, MO, USA) were dissolved in sterile saline (0.9% 
NaCl) and infused 10 min before testing. 
Procedure
Experiment 1. The animals were randomly assigned to 
five groups and infused into the VH either with vehicle or 
RO-60-0175 at the doses of 0.3, 1.0, 3.0 and 10 µg. Infusion 
was achieved by an internal cannula (o.d. 0.3 mm) that 
extended 0.5 mm beyond the guide cannula tip, attached to 
a 10 µl Hamilton syringe via PE-10 tubing. Confirmation 
of successful infusion was obtained by monitoring the 
movement of a small air bubble inside the PE-10 tubing. 
A volume of 0.2 µl/side was delivered over approximately 
30 s with the needle left in place for a further 2 min to 
minimize reflux up to the cannula shaft. 
Ten minutes after infusion, the animals from each group 
were exposed for 5 min to the maze in a counterbalanced 
manner. A highly trained observer who remained blind to 
treatment conditions later analyzed the videotapes. The 
number of entries and the time spent in the open and closed 
arms were recorded. From these measures, the percentage 
of open arm entries (100 x open arm entries/total arm 
entries) and the percentage of time spent in the open arms 
(100 x time open/time open + time closed) were calculated 
for each animal as anxiety-like indexes. In addition to these 
conventional measures, the time displaying risk assessment-
related behaviors from a closed arm (exiting a closed arm 
with the forepaws and head only, and investigating the 
surroundings with horizontal movements of head) was 
recorded as ethologically derived measures of anxiety as 
described elsewhere (Cruz, Frei, & Graeff, 1994). The 
absolute number of closed arm entries was interpreted as 
a reliable index of locomotor activity (File, 1992; Cruz et 
al., 1994).
Experiment 2. In this experiment, four groups of rats 
were exposed to the same EPM procedure described in 
Experiment 1, 10 min after VH infusion either with vehicle 
or the selective 5-HT2C-receptor antagonist RS 102221 at 
the doses of 0.75, 1.25 or 2.5 µg. These doses were chosen 
on the basis of previous studies in which RS 102221 
was administered intracerebrally (McMahon, Filip, & 
Cunningham, 2001; Filip & Cunningham, 2002, 2003; 
Body et al., 2006). 
Histology 
At the end of behavioral testing, the rats were injected 
with sodium thiopental overdoses and a volume of 0.2 
µl fast-green dye was infused into each brain site to 
aid visualize actual injection sites. They were then 
transcardially perfused with physiological saline followed 
by 10% formol-saline solution as fixative. The brains 
were removed, stored in 5% formol-saline for two weeks, 
sectioned horizontally by cryostatic method at 50-60, and 
stained with Cresyl violet. Drawings from the infusion 
locations were superimposed on the appropriate pages of 
the stereotaxic atlas of Paxinos and Watson (1986).
Statistical analysis
Results from the two experiments were statistically 
analyzed by a one-way analysis of variance (ANOVA) 
to detect overall differences. Fisher’s least significant 
difference (LSD) post hoc test was employed to determine 
specific differences between groups. Because the absolute 
number of closed arm entries in Experiment 1 was 
significantly decreased by RO-60-0175, an analysis of 
covariance (ANCOVA) using this parameter as covariant 
(File, 1992) was additionally performed in order to examine 
whether locomotor activity could account for the eventual 
differences in the anxiety-like parameters. The level of 
statistical significance was p < .05.
Results
Histology
As illustrated by a diagrammatic representation of coronal 
sections showing the injection sites from Experiments 1 and 2 
(Figure 1), most of the injections were distributed throughout 
the entire rostral-caudal extent of the target area within the VH. 
Behavioral results from animals with injection sites outside the 
VH (n = 12, Experiment 1; n = 7, Experiment 2) were removed 
from their respective groups and assigned to additional control 
groups in each experiment for statistical analysis.
Behavioral testing 
Experiment 1. Effects of RO-60-0175 on conventional 
measures of exploration in the EPM are shown in Figure 2. 
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As suggested from the upper panel of this figure, the 
ANOVA confirmed a main effect of treatment in both the 
percentage of open arm entries, F (5, 43) = 4.54, p < .05, 
and the percentage of time spent in the open arms, 
F(5, 43) = 6.42, p < .05. Post hoc comparisons showed that 
the doses of 1.0, 3.0 and 10 µg to significantly decreased 
these two parameters of open arm exploration as compared 
to vehicle-infused animals (p < .05). The ANOVA also 
indicated a significant effect of treatment, F(5, 43) = 9.71, 
p < .05, on closed arm entries. Post hoc comparisons 
revealed that the doses of 3.0 and 10.0 µg significantly 
decreased this locomotor activity index as compared to 
vehicle-infused animals (ps < .05).  
To dissociate anxiogenic-like effects from nonspecific 
locomotor impairments induced by the two highest 
RO-60-0175 doses, an additional ANCOVA using the 
closed arm entries as covariant factor was conducted in 
both the percentages of open arm entries and of time spent 
in these arms. In these two cases, the ANCOVA revealed no 
significant effects of treatment when the closed arm entries 
were statistically controlled for (p  > .05). Therefore, the 
decrease in open arm exploration observed at the doses 
of 3.0 and 10.0 µg was probably due to a locomotor 
impairment. 
Figure 2 (lower panel) illustrates the effects of 
RO-60-0175 microinjections on risk assessment. 
The ANOVA indicated a main effect of treatment, 
Figure 1.  Composite of infusion sites aimed at the VH from 
Experiment 1 (white circles) and Experiment 2 (black circles). 
With the reference to the Paxinos and Watson (1986) atlas, the 
numbers on the right side of each plate indicate the distance in 
mm from bregma. 
F(5, 43) = 7.23,  p < .05, and post hoc comparisons 
revealed a significant reduction of risk assessment at the 
doses of 3.0 and 10.0 µg (p < .05 and .01, respectively). No 
other significant differences were found, despite a trend to 
increased risk-assessment at the dose of 1.0 µg. Again, the 
ANCOVA failed to detect significant differences on risk 
assessment parameters when the closed arm entries were 
used as covariate factor (p > .05). 
Experiment 2. Figure 3 shows the effects in the EPM 
of infusing the 5-HT2C-receptor antagonist RS 102221 into 
Figure 2. Mean (+SEM) percentage of open arm entries and 
time (upper panel), closed arm entries (middle panel) and risk 
assessment (lower panel) among groups microinjected either with 
vehicle (n = 7) or RO-60-0175 at the doses of 0.3 µg (n = 8), 1 µg 
(n = 7), 3 µg (n = 9) and 10 µg (n = 7) into the VH. OUT (n = 12) 
illustrates a representative group of rats infused with vehicle or 
different doses of RO-60-0175 at sites localized outside the VH. 
*indicates p < .05 as compared to vehicle control.
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the VH. None of the doses tested significantly affected 
open arm exploration (upper panel) or absolute number of 
closed arm entries. ANOVA outcomes from these anxiety 
and locomotor parameters confirmed a lack of effect of 
RS 102221 (F values not shown). Risk assessment (lower 
panel), however, was significantly changed by treatment, 
F(4,  33) = 5.49, p < .05. Post hoc comparisons revealed 
this effect to be restricted to a single RS 102221 dose (2.5 
µg), which significantly decreased risk assessment-related 
behaviors from the closed arms as compared to vehicle-
infused animals (p < .05).
Pinheiro, Motta, Morato, & Cruz, 1999; Durand, Mormèd, 
& Chaouloff, 2003), whereas its blockage by selective 
5-HT2C antagonists has been appraised as a potential target 
for anxiolytic compounds (Kennett et al., 1997; Bagdy, 
Graf, Anheuer, Modos, & Kantor, 2001; Andres et al., 2002; 
Jones, Duxon, & King, 2002; Martin, Ballard, & Higgins, 
2002; Jones & Blackburn, 2002; Wood, 2003; Gordon, 
2004; Millan, 2005). However, intriguing results ranging 
from anxiolytic-like effects of 5-HT2C receptor agonists 
(Nic Dhonnchadha et al., 2003) to little or null effects of 
5-HT2C receptor antagonists (Griebel, Perrault, & Sanger, 
1997, Griebel, Rodgers, Ghislaine, & Sanger, 1997; Nic 
Dhonnchadha et al., 2003) have also been reported in some 
animal models of anxiety. Moreover, many of these effects 
vary considerably in different postsynaptic 5-HT sites in the 
brain (Jenck, Bos, Wichmann, Stadler, Martin, & Moreau, 
1998; Graeff, Guimaraes, De Andraede, & Deakin, 1996; 
Graeff, 2002; Zanoveli et al., 2003).
In the present study we investigated the effects of two 
selective 5-HT2C-acting compounds microinjected into 
the VH of rats exposed to the EPM. In Experiment 1, the 
selective 5-HT2C agonist RO-60-0175 dose-dependently 
decreased both the percentage of open arm entries and 
the percentage of time spent in the open arms. At the dose 
of 1.0 µg, the RO-60-0175-induced decrease in open-
arm exploration was devoid of a significant locomotor 
interference, despite a clear trend to reduce the absolute 
number of closed arm entries. This anxiogenic-like effect is 
in accordance with the behavioral profile of the preferential 
5-HT2C receptor agonist MK-212 into this same brain 
site (Alves et al., 2004). Taking into account the higher 
selectivity of RO-60-0175 for 5-HT2C receptors, this result 
further corroborates the suggestion that enhanced VH 
5-HT2C-receptor responsiveness is associated with anxiety-
like states.
Because the VH is a postsynaptic 5-HT site notably 
implicated in anxiety (Gray & McNaughton, 2000; 
Degroot & Treit, 2004; Rex et al., 2005), it is possible 
that the present RO-60-0175 effects in the VH might 
involve 5-HT projections from the dorsal raphe nucleus 
(Azmitia & Segal, 1978; Vertes, 1991). In this respect, it 
has been found that potentially dangerous situations such 
as a context previously associated to an aversive stimulus 
(Hajos-Korcsok, 2003) or acute EPM exposure (Wright et 
al., 1992; Voigt et al., 1999; Rex et al., 2005) markedly 
enhance postsynaptic 5-HT levels in the VH. Conversely, 
selective VH lesions attenuate anxiety-related behaviors 
in these animal models of anxiety (Kjelstrup et al., 2002; 
Bannerman et al., 2003). Taking into account the presence 
of the 5-HT2C receptor subtype at a very high density in the 
VH (Pompeiano et al., 1994; Backstrom et al., 1995; Fone 
et al., 1996, Clemett et al., 2000; Garcia-Alcover et al., 
2006), it seems reasonable to assume that 5-HT-induced 
anxiety in the VH might be at least in part mediated via 
5-HT2C-receptor activation. 
It must be noted that the behavioral effects of RO-60-
0175 in the VH resemble those induced by 5-HT2C agonists 
in the amygdala, another important anxiety-related structure 
p o
Figure 3. Mean (+SEM) percentage of open arm entries and 
time (upper panel), closed arm entries (middle panel) and risk 
assessment (lower panel) among groups microinjected either with 
vehicle (n = 7) or RS-102221 at the doses of 0.75 (n = 8), 1.25 
(n = 7) and 2.5  µg (n = 10) into the VH. OUT (n = 7) illustrates 
a representative group of rats infused with vehicle or different 
doses of RS-102221 at sites localized outside the VH. *indicates 
p < .05 as compared to vehicle control.
Discussion
Pharmacological activation at 5-HT2C receptors is 
associated with anxiety states and locomotor suppressant 
effects (Kennett, Whitton, Shah, & Curzon, 1989; Rodgers 
et al., 1992; Griebel et al., 1994; Wallis & Lal, 1998; Setem, 
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(LeDoux, Iwata, & Cichetti, 1988; Davis, Raiunnie, & 
Cassell, 1994; Davis & Shi, 1999) innervated by 5-HT fibers 
from the dorsal raphe nucleus (Vertes, 1991; Rainnie, 1999). For 
example, infusions of the nonselective 5-HT2C agonist mCPP 
and the selective 5-HT2C agonist IL-639 into the basolateral 
nucleus of the amygdala produced ultrasonic vocalization 
and increased the latency to investigate new objects in rats 
exposed to an open-field, an anxiogenic-like effect prevented 
by intraperitoneal (IP) pretreatment with the selective 5-HT2C 
antagonist SB-24084 (Campbell & Merchant, 2003). In the 
same line of evidence, our recent plus-maze results (Cruz et al., 
2005) with basolateral amygdala infusion of ritanserin, a mixed 
5-HT2 blocker that exhibits higher affinity at 5-HT2C than 
5-HT2A receptors (Leysen et al., 1986; Leysen, 2004), show 
that this compound was able to prevent decreased open arm 
exploration induced by IP injection of MK-212. Interestingly, 
in this same study, ritanserin microinfusion into the basolateral 
amygdala was ineffective to change basal anxiety-like levels 
in saline-pretreated animals. It seems, therefore, that 5-HT2C 
receptors within both the VH and basolateral nucleus of the 
amygdala play a similar role in mediating fear or anxiety-
related behaviors. This view is supported by the existence 
of a bilateral neural projection between the VH and several 
nuclei of the amygdaloid complex (for a review, see Pitkanen, 
Pikkarainen, Nurminen, & Ylinen, 2000). 
Deakin and Graeff (1991) have proposed a dual role 
of 5-HT action on anxiety mediation. According to this 
hypothesis, ascending fibers from the dorsal raphe nucleus 
might facilitate anxiety through actions on the amygdala, 
while inhibiting inborn fight/flight reactions in the 
periaqueductal gray. Although this model recognizes the 
participation of an anatomical projection from the MRN 
to the dorsal hippocampus in the resistance to chronic and 
inescapable aversive stimuli, no mention is made regarding 
the 5-HT projections from the DRN to the VH. Our results 
suggest that 5-HT2C receptors located within the VH might 
modulate anxiety behavior in a similar way to that attributed 
to the amygdala by Deakin and Graeff in their model.
It is important to acknowledge that direct comparisons 
between the effects of selective lesions of either the VH 
or the amygdala have suggested these structures to be 
functionally distinct in the control of defensive behaviors. 
For example, VH but not amygdala lesions produced 
anxiolytic-like effects in widely used animal models of 
anxiety such as the EPM (Sommer et al., 2001; Kjelstrup 
et al., 2002; McHugh et al., 2004), the successive alleys 
test (McHugh et al., 2004) and the social interaction in rats 
(Decker, Curzon, & Brioni, 1995; McHugh et al., 2004). It 
is still unclear whether these differences are task-dependent 
or related to specific nuclei of the amygdala. 
Results from Experiment 1 also showed the doses of 3.0 and 
10.0 µg of RO-60-0175 to markedly reduce closed arm entries, 
a behavioral profile indicative of decreased locomotor activity 
in the EPM. This is in agreement with the well-documented 
locomotor-suppressant effects of systemically administered 
5-HT2C agonists, including RO-60-0175 (Martin et al., 1998, 
Kennett et al., 2000; Martin et al., 2002).
As confirmed by the ANCOVA, the RO-60-0175-
induced locomotor interference was observed exclusively 
at the two highest doses. This decrease in general activity 
practically abolished the occurrence of risk assessment-
related behaviors. However, this effect cannot be 
interpreted as an anxiolytic-like action. As we previously 
reported (Cruz et al., 1994), a lack of risk assessment upon 
high anxiety levels that are accompanied by a significant 
decrease of closed arm entries most probably reflects 
decreased general exploration or even complete immobility 
inside the closed arms. Therefore, the present results also 
suggest that the VH 5-HT2C receptors might play a role in 
mediating locomotor activity. 
As far as we know, this is the first report in the 
literature that tested the behavioral effects of RO-60-0175 
microinjected into the VH. The locomotor activity effect 
observed in the present study was also reported by Fletcher 
and colleagues (2004), who found that microinjections of the 
same dose range of RO-60-0175 into the ventral tegmental 
area also impaired locomotor activity. Therefore, it appears 
that 5-HT2C in different brain areas might be involved in 
the mediation of locomotor activity. At least in part, this 
view is corroborated by our results, which found the group 
microinjected with RO-60-0175 outside the VH to show 
a trend toward reducing closed arm entries, although this 
effect was not statistically significant.  
In Experiment 2, VH infusion of the selective 
5-HT2Cagonist RS 102221 did not affect conventional 
parameters of EPM exploration. At the two highest doses, 
however, RS 102221 significantly reduced risk assessment. 
Considering that a reduction in risk assessment in the 
absence of locomotor effects is consistent with a selective 
anxiolytic-like action in the EPM (Cruz et al., 1994; 
Griebel et al., 1997a, 1997b), our results suggest that the 
VH 5-HT2C receptor blockade might be associated with a 
reduction of anxiety-like states. 
Frequency and/or duration of risk assessment-related 
behaviors from the closed arms have been widely used 
in the EPM scoring as a reliable and sensitive measure to 
detect anxiolytic-like effects of 5-HT compounds (Griebel 
et al., 1997a, 1997b; Setem et al., 1999; Griebel, Rodgers, 
Perrault, & Sanger, 2000), which does not necessarily 
change the conventional parameter of anxiety in this test. 
Factor analyses of spatiotemporal and ethologically derived 
measures of rats in the EPM indicated that although risk 
assessment and conventional anxiety measures loaded in 
the same factor, the former but not the latter also loaded 
in another factor seemingly related to decision-making 
processes or more cognitively oriented aspects of anxiety 
(Cruz et al., 1994). Therefore, it can be concluded from the 
present results that RS 102221 microinfusion into the VH 
induced an anxiolytic-like action as measured by the risk 
assessment in the EPM.         
The possibility that the conventional anxiety measures 
might be less sensitive in detecting anxiolytic-like action 
of 5-HT2 antagonists upon low basal levels of anxiety in 
the EPM cannot be discounted (Rodgers & Dalvi, 1997). 
In fact, substantial experimental evidence indicates that, 
whereas 5-HT2C agonists decrease open arm exploration, 
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an anxiogenic-like action that is prevented by selective 
and nonselective 5-HT2C antagonists, the blockade 
of 5-HT2Creceptors by itself had little or no effect on 
conventional anxiety parameters in the EPM (Griebel, 
1996; Griebel et al., 1997a, 1997b; Setem et al., 1999, Jones 
et al., 2002; Martin et al., 2002). In line with this view, we 
reported that the nonselective blockade of 5-HT2C receptors 
in the basolateral nucleus of the amygdala prevented MK-
212-induced decrease in open arm exploration, whereas 
the blockade of this receptor by itself was ineffective in 
saline pretreated animals (Cruz et al., 2005). 
Finally, the use of inadequate doses cannot be totally 
excluded from the lack of clear effects of RS 102221 on 
open arm exploration. Although the effects of similar RS 
102221 dose ranges have been investigated in different brain 
areas (e.g. McMahon et al., 2001; Filip & Cunningham, 
2002), this is first study in which the effects of intra-VH 
RS 102221 infusion was investigated in anxiety-like 
behaviors of rats exposed to the EPM. Therefore, further 
experiments comparing the effects of other dose ranges 
and other selective 5-HT2C agonists and antagonists in both 
conventional and ethologically derived measures in the 
EPM could improve our knowledge about the involvement 
of 5-HT2C receptors on anxiety mediation. 
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